20th International Congress » Parkinson's disease: Clinical trials, pharmacology and treatment

12:00pm-1:30pm

A combined therapeutic approach in the management of abnormal postures in Parkinson’s disease

S. Di Martino, E. Unti, C. Tramonti, S. Mazzucchi, U. Bonuccelli, B. Rossi, R. Ceravolo, C. Chisari (Pisa, Italy)

12:00pm-1:30pm

A comparison of deep brain stimulation and continuous intrajejunal levodopa infusion in advanced Parkinson’s disease: The INVEST study

D. van Poppelen, R.M.A. de Bie, J.M. Dijk (Amsterdam, Netherlands)

12:00pm-1:30pm

A national case study of virtual care visits for Parkinson’s disease (RACE-PD): Interim assessment of participant and investigator experiences

R. Korn, H.T. Keenan, T. Felong, S. Goldenthal, S. Kanchana, H. Schwarz, S. Sharma, K. Andrzejewski, E.A. Stevenson, R. Barbano, G. Kang, K. Rizer, A. Shukla, M.J. Dodge, C. Tanner, M. Katz, R. Rodriguez, N. Galifianakis, W. Zhu (Rochester, NY, USA)

12:00pm-1:30pm

A phase II, pragmatic, randomized clinical trial on a high-intensity exercise and fall prevention boot camp for Parkinson’s disease: Feasibility and safety

M.R. Landers, J.W. Navalta (Las Vegas, NV, USA)

12:00pm-1:30pm

A phase II, pragmatic, randomized clinical trial on a high-intensity exercise and fall prevention boot camp for Parkinson’s disease: Signal of efficacy

M.R. Landers, J.W. Navalta (Las Vegas, NV, USA)

12:00pm-1:30pm

A randomized controlled clinical study to evaluate efficacy, safety and tolerability of SC L-dopa/carbidopa (ND0612H) infusion regimens in fluctuating PD patients

K. Kieburtz, C.W. Olanow, Y. Cohen, S. Oren (Rochester, NY, USA)

12:00pm-1:30pm

Activities of daily living and motor scores of the UPDRS in fluctuating Parkinson’s disease patients treated with opicapone

J. Ferreira, A. Lees, O. Rascol, T. Müller, A. Santos, I. Oliveira, N. Lopes, J.F. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

12:00pm-1:30pm

Adenosine A2A receptor antagonist istradefylline might have efficacy to fatigue and depression in some patients of Parkinson’s disease

H. Ito, T. Kamei (Fujisawa, Japan)

12:00pm-1:30pm

AntiParkinsonian treatment patterns and motor complications among patients with Parkinson´s disease in Estonia

L. Kadastik-Eerme, N. Taba, P. Taba (Tartu, Estonia)

12:00pm-1:30pm

Apomorphine treatment in advanced Parkinson’s disease (PD): Duration of treatment and safety experience in a managed care program in Germany

D. Maessen, G. Ebersbach, L. Timmermann, A. Ceballos-Baumann (Düsseldorf, Germany)

12:00pm-1:30pm

Association of Parkinson’s disease with essential tremor

D. Aygun (Samsun, Turkey)

12:00pm-1:30pm

Association of the DRD2 (CA) n and DRD3 Ser9Gly polymorphisms with Parkinson’s disease and response of dopamine agonists

S. Xu, J. Liu, X. Yang, Y. Qian, Q. Xiao (Shanghai, People's Republic of China)

12:00pm-1:30pm

Auditory cues during obstacle crossing increase gait asymmetry in neurologically health individuals but not in people with Parkinson’s disease

M.B. Pestana, L.T.B. Gobbi, L. Simieli, D. Orcioli-Silva, A.M. Baptista, V.S. Beretta, P.C.R. Santos, T. Penedo, V.I.A. Pereira, F.A. Barbieri (Rio Claro, Brazil)

12:00pm-1:30pm

Balance and gait disturbances in Parkinson’s disease patients with falls and freezing of gait

J. Stozek, M. Rudzinska, S. Bukowczan, A. Szczudlik (Cracow, Poland)

12:00pm-1:30pm

Balance training in individual’s with Parkinson’s disease: Therapist-supervised vs. home-based exercise programmes

E.M. Atterbury, K.E. Welman (Stellenbosch, South Africa)

12:00pm-1:30pm

Best supportive care or palliative care for late stage Parkinsonian syndromes?

S. Lorenzl, C. Richinger, C. Schmotz, G. Nübling (Salzburg, Austria)

12:00pm-1:30pm

Biseptol a new antiParkinsonian agent?

K. Karpinska, V. Smolanka (Uzhgorod, Ukraine)

12:00pm-1:30pm

Blindfolded balance training in patients with Parkinson’s disease: A sensory-motor strategy to improve the gait

A. Peppe, S. Bonnì, M. Fabio, K. Giacomo, A. Martino Cinnera, M. Tramontano, C. Caltagirone (Rome, Italy)

12:00pm-1:30pm

Body position during sleep in patients with Parkinson’s disease (PD): A sensor-based analysis

J. Sringean, P. Taechalertpaisarn, C. Thanawattano, R. Bhidayasiri (Nonthaburi, Thailand)

12:00pm-1:30pm

Can hospital admissions predict mortality in Parkinson’s?

B. Mohamed, N. Leopold, C. Thomas (Cardiff, United Kingdom)

12:00pm-1:30pm

Can treadmill training facilitate the dual-task gait in Parkinson’s disease?

A.V.C. Sousa, L.M.M. Santiago, R.E.O. Silva, A.P. Spaniol, D.A. Oliveira, É.R.V.P. Galvão, T.S. Ribeiro, A.R.R. Lindquist (Natal, Brazil)

12:00pm-1:30pm

Changes in handwriting following repetitive transcranial magnetic stimulation over pre-motor cortex in Parkinson’s disease

A.Y. Son, M.C. Biagioni, E. Pirraglia, A. DiRocco (New York, NY, USA)

12:00pm-1:30pm

Clinical and biological predictors of time to initiation of symptomatic therapy in early Parkinson’s disease

T. Simuni, J. Long, C. Caspell-Garcia, C.S. Coffey, S. Lasch, C. Tanner, D. Jennings, K. Kieburtz, K. Marek, On behalf of the PPMI Investigators (Chicago, IL, USA)

12:00pm-1:30pm

Clinical effect and dose conversion of rytary (numient) in 50 consecutive patients with PD motor fluctuations

N. Chhabria, S.H. Isaacson (Boca Raton, FL, USA)

12:00pm-1:30pm

Computational assessment of calcium channel effects on subthalamic nucleus neuronal cells: Study of abnormal bursting patterns in Parkinson’s disease

C. Mahapatra, R. Manchanda (Mumbai, India)

12:00pm-1:30pm

Continuous subcutaneous delivery of solubilized carbidopa improves the pharmacokinetic profile of levodopa

R. Shaltiel-Karyo, E. Zawoznik, I. Weinstock, M. Nemas, Y. Caraco, P.A. LeWitt, S. Oren, O. Yacoby-Zeevi (Rehovot, Israel)

12:00pm-1:30pm

Contributions of sensorial feedback to gait in Parkinson’s disease

F.A. Barbieri, L.T.B. Gobbi, P.C.R. Santos, R. Vitório, L. Simieli, D. Orcioli-Silva, M.B. Pestana, C.M. Fiorelli, Q. Almeida (Bauru, Brazil)

12:00pm-1:30pm

Conversion of patients from immediate release carbidopa-levodopa (IR CD-LD) and sustained release carbidopa-levodopa (SR CD-LD) to extended-release carbidopa-levodopa (ER CD-LD) in clinical practice

S.J. LoRusso, B. Ouyang, B.R. Barton (Chicago, IL, USA)

12:00pm-1:30pm

Conversion to IPX066, extended-release carbidopa-levodopa, in advanced Parkinson’s disease patients: Dosing patterns

J. Morgan, M. Stacy, R. Rubens, S. Khanna, S. Gupta (Augusta, GA, USA)

12:00pm-1:30pm

Correlation between Parkinson’s disease and malignant tumors

E. Binaghi, M.M. Mascia, P. Solla, M. Meloni, R. Farris, D. Ciaccio, G. Orofino, F. Marrosu, A. Cannas (Cagliari, Italy)

12:00pm-1:30pm

Creatine for patients with Parkinson’s disease: A meta-analysis

A. Attia, H. Ahmed, M. Morsi, K. Awad, M. Elnenny, E. Ghanem, A. Negida (Cairo, Egypt)

12:00pm-1:30pm

Creativity related to dopaminergic treatment. A multicenter study

P.J. Garcia Ruiz, J.C. Martinez Castrillo, L. Vela (Madrid, Spain)

12:00pm-1:30pm

Critical path for Parkinson’s, I: Data sharing and regulatory science in catalyzing innovation for Parkinson’s disease

K. Romero, D. Burn, M. Hu, A. Yarnell, C. Williams Gray, K. Marek, D. Grosset, M. Sutherland, M. Isaac, A. Bhattaram, V. Sinha, M.F. Gordon, P. Muglia, L. Slicker, W. Hirst, M. Facheris, J. Posener, M. Bani, B. Corrigan, R. Schindler, K. Tsai, T. Nicholas, J. Cedarbaum, J. Gallagher, S. Ford, E. Avilex, V. Kern, S. Arneric, D. Stephenson, A. Roach (Tucson, AZ, USA)

12:00pm-1:30pm

Day case initiation of subcutaneous apomorphine in people with Parkinson’s disease: A retrospective analysis from a UK teaching hospital

K. Nalamada, J. Cosgrove, P. Duggan-Carter, S. Jamieson, J. Alty (Leeds, United Kingdom)

12:00pm-1:30pm

Development of a nanoherbaceutical formulation containing compound extracts from huperzia serrata, mucuna pruriens and withania somnifera for the prevention and treatment of Parkinson’s disease

V. Kumar, P.C. Bhatt (Allahabad, India)

12:00pm-1:30pm

Diagnostic value of a new coronal examination plane in transcranial nigral sonography and of additional M-mode tremor frequency determination for the differentiation of idiopathic Parkinson’s disease and essential tremor

L. Tönges, R. Daniel, D. Woitalla, S. Muhlack, R. Gold, C. Krogias (Bochum, Germany)

12:00pm-1:30pm

Differential clinical outcomes in unifocal vs. multifocal premotor rTMS for Parkinson’s disease: A randomized trial

M.C. Biagioni, A.Y. Son, S. Agarwal, G. Dacpano, M. Brys, P. Kumar, A. Cucca, J. Singleton-Garvin, R. Gilbert, A. Quartarone, A. DiRocco (New York, NY, USA)

12:00pm-1:30pm

Differential effects of tango, treadmill, and stretching interventions on gait in people with Parkinson’s disease

M.E. McNeely, R.P. Duncan, G.M. Earhart (St. Louis, MO, USA)

12:00pm-1:30pm

DIRECT DBS: A prospective, multi-center clinical trial with blinding for a directional DBS lead

J. Volkmann, S. Chabardes, G.K. Steinke, S. Carcieri, N. Van Dyck (Wuerzberg, Germany)

12:00pm-1:30pm

Diurnal variation of levodopa plasma concentration in patients with Parkinson’s disease

M. Nagai, M. Kubo, H. Iwaki, R. Ando, H. Yabe, N. Nishikawa, M. Nomoto (Ehime, Japan)

12:00pm-1:30pm

Diverse effects of alpha-synuclein fibrils on various neuron cell lines, using different buffers

F. Aliakbari, D. Morshedi, A.A. Shabani, H. Mohammad Beigi, A. Tayaranian Marvian, P. Shariati, S.A. Shojaosadati, A.A. Saboury (Semnan, Islamic Republic of Iran)

12:00pm-1:30pm

Does distance walked after two minutes predict total 6 minute walk test distance in people with Parkinson’s disease?

R.P. Duncan, M.E. McNeely, G.M. Earhart (Saint Louis, MO, USA)

12:00pm-1:30pm

Does physical exercise influence the cognitive domains that predict dementia in Parkinson’s disease?

C.R.A. Silveira, E.A. Roy, B.N. Intzandt, Q.J. Almeida (Waterloo, ON, Canada)

12:00pm-1:30pm

Dopamine dysregulation syndrome /DDS/ in LCIG infusion: Successful treatment without interrupting the pump therapy

A. Tóth, H. Nagy, S. Funk, A. Takáts (Budapest, Hungary)

12:00pm-1:30pm

Dopaminergic medication effect on speech in Parkinson’s disease: A kinematic study

T.E. Tong, M.L. Ng, N. Yan (Hong Kong, Hong Kong)

12:00pm-1:30pm

Drug safety in the pharmacotherapy of Parkinson’s disease

S. Müller-Rebstein, C. Trenkwalder, J. Ebentheuer, C. Culmsee, G. Höglinger (Kassel, Germany)

12:00pm-1:30pm

Duloxetine, a serotonin and norepinephrine reuptake inhibitor, reduces daily OFF time in Parkinson’s disease

M. Tomiyama, Y. Funamizu, T. Kon, R. Haga, T. Ueno, H. Nishijima, A. Arai, C. Suzuki, J.I. Nunomura, M. Baba (Aomori, Japan)

12:00pm-1:30pm

Duodenal levodopa infusion: Safety and efficacy in a 6 years outpatient follow-up

S. Simoni, N. Tambasco, E. Sacchini, P. Nigro, F. Ripandelli, P. Calabresi (Perugia, Italy)

12:00pm-1:30pm

Duodopa treatment experience in Oradea

M. Sabau, L. Botnaru, A. Badea, C. Dudas (Oradea, Romania)

12:00pm-1:30pm

Dynamic prediction for multiple repeated measures and event time data: An application to Parkinson’s disease

S. Luo, J. Wang (Houston, TX, USA)

12:00pm-1:30pm

Effect of over(exaggerated) articulation technique in voice and speech of individuals with Parkinson’s disease with deep brain stimulation

G.L.A. Diaféria, F.A.M. Bento, M. Padovani, E.T. Fonoff, M.S. Behlau (São Paulo, Brazil)

12:00pm-1:30pm

Effect of repeated intravenous amantadine infusions in patients with Parkinson’s disease

A. Khlebtovsky, I. Steiner, R. Djaldetti, T. Treves (Petach Tikva, Israel)

12:00pm-1:30pm

Effectiveness of a multidisciplinary PD clinic in improving quality of life

H.F. Chan, D.K.W. Chau, T. Fung, I. Chan, Y.F. Cheung, W.C. Fong (Hong Kong, Hong Kong)

12:00pm-1:30pm

Effectivity and safety of rotigotine transdermal patch on motor and cognitive dysfunctions in Parkinson’s disease with dementia and dementia with Lewy bodies

K. Ohta, Y. Kujuro, T. Osada, T. Toguchi, Y. Shinohara (Tokyo, Japan)

12:00pm-1:30pm

Effects of combined repetitive transcranial magnetic stimulation and treadmill training on gait performance in Parkinson’s disease

C.L. Chung, M.K.Y. Mak (Hong Kong, Hong Kong)

12:00pm-1:30pm

Effects of exercise intervention on balance and gait performance, and balance confidence in people with Parkinson’s disease – A meta-analysis

M.K. Mak, I.S. Wong-Yu (Hong Kong, People's Republic of China)

12:00pm-1:30pm

Effects of levodopa on adaptation of reactive stepping in people with Parkinson’s disease

F.B. Horak, B. Dijstra, J.G. Nutt, D.S. Paterson (Portland, OR, USA)

12:00pm-1:30pm

Effects of nilotinib on safety in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia

F. Pagan, E. Valadez, Y. Torres-Yaghi, R. Falconer, R. Mills, S. Rogers, B. Wilmarth, M. Hebron, C. Moussa (Washington, DC, USA)

12:00pm-1:30pm

Effects of plantar automated mechanical stimulation (AMPS) on motor symptoms of patients with advanced Parkinson’s disease: Preliminary data of a double blind randomized clinical trial

L. Bartolomei, M. Malaguti, A. Pastore, G.M. Minicuci, N. Bonetto, S. Ferrari, M. Pellegrini (Vicenza, Italy)

12:00pm-1:30pm

Effects of pyridostigmine bromide vs. fludrocortison in the treatment of orthostatic hypotension in Parkinson’s disease

S.R. Schreglmann, F. Büchele, M. Sommerauer, L. Epprecht, G. Kägi, S. Hägele-Link, O. Götze, L. Zimmerli, D. Waldvogel, C.R. Baumann (London, United Kingdom)

12:00pm-1:30pm

Effects of safinamide in patients with Parkinson’s disease measured by Parkinson’s KinetiGraphTM

I. Suttrup, V. Zentsch, J. Schroeder, T. Warnecke (Muenster, Germany)

12:00pm-1:30pm

Effects of videogame step training on gait adaptability in people with Parkinson´s disease – A randomized controlled trial

M.J.D. Caetano, J.C. Menant, C.G. Canning, J. Song, D. Schoene, M. Brodie, S.R. Lord (Sydney, Australia)

12:00pm-1:30pm

Efficacy and feasibility study of the Medido eletronic medication dispenser in Parkinson’s disease: A multicentre randomized controlled trial

K. Hannink, L. ter Brake, A. Wertenbroek, K. Movig, J. van der Palen, L. Dorresteijn (Enschede, Netherlands)

12:00pm-1:30pm

Efficacy of apomorphine subcutaneous injections in patients with levodopa dose failures and morning akinesia

S.H. Isaacson (Boca Raton, FL, USA)

12:00pm-1:30pm

Efficacy of long-term treatment with istradefylline and analysis of the expression of A2A receptor protein and post-transcriptional DNA methylation

N. Kanzato, K. Nakachi, T. Naka, M. Higa, S. Mochizuki, Y. Miyamae (Okinawa Prefecture, Haebaru-cho, Japan)

12:00pm-1:30pm

Eight weeks of home-based balance training not as effective as therapist-based during dual tasks

E.M. Atterbury, K.E. Welman (Stellenbosch, South Africa)

12:00pm-1:30pm

Elemental profiles as biomarkers for diagnosis and disease progression of Parkinson’s disease

F. Maass, M. Börger, A. Fischbach, B. Michalke, M. Bähr, I. Zerr, P. Lingor (Göttingen, Germany)

12:00pm-1:30pm

Engrailed enhances dopamine synthesis in healthy dopaminergic neurons

D. Alvarez-Fischer, M. Baaske, F. Vulinovic, J. Fuchs, P. Seibler, A. Rakovic, A. Prochiantz, C. Klein (Lübeck, Germany)

12:00pm-1:30pm

Establishment of InMotion, an independent, fee-free community center for persons with movement disorders

D.E. Riley, K.M. Jaffe, J.Z. Peters (Warrensville Heights, OH, USA)

12:00pm-1:30pm

Evaluation of droxidopa dosing and clinical response in 50 consecutive patients with Parkinson’s disease and symptomatic neurogenic orthostatic hypotension

S.H. Isaacson, S. Brillman, N. Chhabria (Boca Raton, FL, USA)

12:00pm-1:30pm

Evaluation of impulse control disorders in fluctuating Parkinson’s disease patients under opicapone treatment

N. Lopes, J. Ferreira, A. Lees, T. Müller, H. Reichmann, H. Gama, A. Santos, C. Oliveira, J.F. Rocha, P. Soares-da-Silva (Coronado, Portugal)

12:00pm-1:30pm

Exercise-induced adaptive neuroplasticity in the MPTP mouse model of Parkinson’s disease

C.J.H.M. Klemann, G. Poelmans, G.J.M. Martens, J.E. Visser (Nijmegen, Netherlands)

12:00pm-1:30pm

Experience with utilization of rytary in the clinical setting

Y. Kianirad, T. Simuni, C. Zadikoff, D. Bega, M. Afshari, S. Jonnalagadda (Chicago, IL, USA)

12:00pm-1:30pm

Expiratory muscle training for the impaired loudness of speech in Parkinson’s disease: An open-label study

S. Tomita, T. Oeda, A. Umemura, M. Kohsaka, K. Park, K. Yamamoto, H. Sugiyama, H. Sawada (Kyoto, Japan)

12:00pm-1:30pm

Exploratory efficacy of opicapone in fluctuating Parkinson’s disease patients at different stages of symptom progression

N. Lopes, J. Ferreira, A. Lees, W. Poewe, H. Reichmann, A. Santos, C. Oliveira, J.F. Rocha, P. Soares-da-Silva (Porto, Portugal)

12:00pm-1:30pm

Exploring therapeutic viability of a non-dopaminergic target for Parkinson’s disease

A. Ashrafi, M. Buttini, P. Garcia, A. del Sol, E. Glaab (Esch-sur-Alzette, Luxembourg)

12:00pm-1:30pm

Extended-release carbidopa-levodopa, IPX066: Dosing and efficacy with concomitant medication use in Parkinson’s disease

S. Gupta, S. Khanna, S. Kell, R. Rubens (Hayward, CA, USA)

12:00pm-1:30pm

Falls and frailty predicate escalating care needs in Parkinson’s disease

B. Mohamed, C. Thomas, H. Shukla, S. Aithal (Cardiff, United Kingdom)

12:00pm-1:30pm

Feasibility and preliminary efficacy of a telehealth approach to group tango instruction for people with Parkinson’s disease

K.J. Seidler, R.P. Duncan, M.E. McNeely, M.E. Hackney, G.M. Earhart (St. Louis, MO, USA)

12:00pm-1:30pm

Feasibility of implementing a long-term mobile device program in PD patients

L.R. Bataille, L.D. Herron, M. Afek, I. Feldman, C. Admati, S. Chowdhury (New York, NY, USA)

12:00pm-1:30pm

Feasibility, safety and effects of a group intervention based on European physiotherapy guideline for Parkinson´s disease

J.E. Pompeu, T.B. Freitas, R.A. Nuvolini, K.G. Silva, F. Doná, R.A. Andreotti, N.A. Mazzini, M.G.R. Almeida, C. Torriani-Pasin (Sao Paulo, Brazil)

12:00pm-1:30pm

Fighting Freezing of gait in Parkinson’s disease: Effect of a phase-dependent tactile biofeedback

M. Mancini, K. Smulders, G. Harker, A.C. Fortaleza, J.G. Nutt, F.B. Horak (Portland, OR, USA)

12:00pm-1:30pm

Fox insight wear ecosystem: using mobile technology and cloud-based computing to support PD research

I. Feldman, M. Afek, L. Bataille (Gedera, Israel)

12:00pm-1:30pm

Group climate in the voice therapy of patients with Parkinson’s disease

G.L.A. Diaféria, P.B. Takaki, G. Madazio, C. Pacheco, M.S. Behlau (São Paulo, Brazil)

12:00pm-1:30pm

Healthcare burden of Parkinson’s disease

M. Tagliati, A.T. Connolly (Los Angeles, CA, USA)

12:00pm-1:30pm

Histology of subcutaneous nodules in PD patients treated with continuous apomorphine infusion: Case series and review of the literature

R.W.K. Borgemeester, G.F.H. Diercks, M.L.A. Schuttelaar, T. van Laar (Groningen, Netherlands)

12:00pm-1:30pm

Hospitalisation following different initial therapies in early Parkinson’s disease: Analysis of hospital episodes statistics from the PD MED EARLY trial

S. Muzerengi, R.L. Woolley, C. Rick, N. Ives, F. Dowling, R. Gray, C.E. Clarke, PD MED Collaborative Group (Birmingham, United Kingdom)

12:00pm-1:30pm

Human-derived α-synuclein antibody BIIB054 binds pathologic forms of α-synuclein and attenuates transmission of α-synuclein in vitro and in vivo

A. Weihofen, H. Patel, C. Huy, C. Liu, I. Combaluzier, S. Mueller-Steiner, N. Cavegn, L. Strobel, T.M. Engber, K.J. Rhodes, C. Hock, R.M. Nitsch, F. Montrasio, J. Grimm, A. Dunah, P.H. Weinreb (Cambridge, MA, USA)

12:00pm-1:30pm

Improved motor functioning of people with Parkinson’s disease following dance intervention

S.M. Simone, K.A. Beben, S.E. Maguire, C. Noudga, K.L.M. Martin, G.N. Luabeya, P. Dhami, R.J. Bar, J.F. DeSouza (Toronto, ON, Canada)

12:00pm-1:30pm

Improvement in posture, pain, and cardiac autonomic function in a prospective study of osteopathic manipulative medicine and physical therapy for camptocormia in Parkinson’s disease

J.D. Mancini, D.M. Pasternack, N. Caruana, A. Leder (Old Westbury, NY, USA)

12:00pm-1:30pm

Improvement of freezing of gait with intestinal levodopa infusion in advanced Parkinson’s disease patients

M. Zibetti, S. Angrisano, F. Dematteis, A. Romagnolo, A. Merola, L. Lopiano (Torino, Italy)

12:00pm-1:30pm

Improving drug discovery using brain oscillations as biomarkers of Parkinson’s disease

B. Pouyatos, S.J. Perry, D.E. Grigoriadis, R. Maury, C. Bouyssières, C. Roucard, V. Duveau, Y. Roche (La Tronche, France)

12:00pm-1:30pm

Improving provision of Parkinson’s disease exercise classes

C. Carroll, P. Pujara, J. Rideout (Plymouth, United Kingdom)

12:00pm-1:30pm

Influence of treadmill gait training with additional load on motor function, postural instability and history of falls for individuals with Parkinson’s disease: A randomized clinical trial

L.C.L. Trigueiro, A.V.C. Sousa, G.L. Gama, T.S. Ribeiro, L.G.L.M. Ferreira, C.R. Simão, É.R.V.P. Galvão, E.M.G.S. Silva, C.G. Júnior, A.R.R. Lindquist (Natal, Brazil)

12:00pm-1:30pm

Inhibition of glucosylceramide synthase reduces pathology and improves cognition in synucleinopathy murine models

L. Shihabuddin, C. Viel, J. Clarke, H. Park, J.C. Dodge, J. Marshall, B. Wang, S.H. Cheng, S.P. Sardi (Framingham, MA, USA)

12:00pm-1:30pm

Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term efficacy results on motor complications from the GLORIA registry

W. Poewe, T. Kimber, B. Bermans, P. Odin, A. Antonini, O. Bajenaru, K. Onuk, A. Yegin, L. Bergmann, K.R. Chaudhuri (Innsbruck, Austria)

12:00pm-1:30pm

Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term non-motor, quality of life and safety results from the GLORIA registry

K.R. Chaudhuri, Z. Pirtosek, B. Pickut, W. Poewe, F. Valldeoriola, L. Defebvre, R. Jech, P. Odin, C. Winkler, J. Szasz, K. Onuk, A. Yegin, L. Bergmann, A. Antonini (London, United Kingdom)

12:00pm-1:30pm

Levodopa/carbidopa intestinal gel, neuropathy, and B-vitamins – Is there an association?

S. Löns, E. Chorbadgieva, A. Kleimann, D. Dressler, C. Schrader (Hannover, Germany)

12:00pm-1:30pm

Medication use patterns vary across expert Parkinson’s disease clinics

P. Schmidt, F. Cubillos, T. Simuni, C. Marras, T. Davis, E.C. Nelson (Miami, FL, USA)

12:00pm-1:30pm

Medicinal cannabis for Parkinson’s disease: A survey of practices, beliefs, and attitudes among providers at NPF centers of excellence

D. Bega, T. Simuni, M.S. Okun, P. Schmidt (Chicago, IL, USA)

12:00pm-1:30pm

Minimizing levodopa titration period for Parkinson’s disease (PD)

I. Thomas, M. Alam, D. Nyholm, M. Senek, J. Westin (Falun, Sweden)

12:00pm-1:30pm

Motor fluctuations in relation to plasma concentrations following a single-dose of levodopa/carbidopa microtablets in advanced Parkinson’s disease

M. Senek, H. Askmark, S.M. Aquilonius, F. Bergquist, R. Constantinescu, A. Ericsson, S. Lycke, A. Medvedev, M. Memedi, F. Ohlsson, J. Spira, J. Westin, D. Nyholm (Uppsala, Sweden)

12:00pm-1:30pm

Motor phenotype classification in moderate to advanced PD: Data from the BioFIND study

L. Luo, H.F. Andrews, J.G. Goldman, R.N. Alcalay, T. Xie, P. Tuite, C. Henchcliffe, P. Hogarth, A. Amara, S. Frank, A. Rudolph, C. Casaceli, K. Gwinn, M. Sutherland, C. Kopil, L. Vincent, M. Frasier, U.J. Kang (New York, NY, USA)

12:00pm-1:30pm

Multidisciplinary Parkinson rehabilitation in the Netherlands: The effectiveness of points of Parkinson (POP)

E.T. Steendam-Oldekamp, W.A.W.F. Rutgers, T. van Laar (Groningen, Netherlands)

12:00pm-1:30pm

ND0701: A novel safe concentrated apomorphine formulation for continuous subcutaneous administration via a patch pump

R. Shaltiel-Karyo, Y. Tsarfati, E. Zawoznik, I. Weinstock, M. Nemas, A. Rubinski, Y.S. Schiffenbauer, A. Nyska, O. Yacoby-Zeevi (Rehovot, Israel)

12:00pm-1:30pm

New therapeutic algorithm for abnormal posture in Parkinson’s disease and related disorders

Y. Mukai, Y. Furusawa, Y. Aoshima, H. Todo, Y. Hama, C. Matsumoto, N. Wakasugi, Y. Mizuno, T. Kawazoe, Y. Saitoh, T. Sakamoto, M. Murata (Tokyo, Japan)

12:00pm-1:30pm

Nilotinib improves motor skills, cognition and autonomic function in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia

F. Pagan, E. Valadez, Y. Torres-Yaghi, A. Keys, R. Falconer, S. Rogers, B. Wilmarth, M. Hebron, C. Moussa (Washington, DC, USA)

12:00pm-1:30pm

Nilotinib significantly alters CSF biomarkers and increases endogenous dopamine in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia

C. Moussa, E. Valadez, Y. Torres-Yaghi, A. Keys, R. Falconer, S. Rogers, B. Wilmarth, M. Hebron, F. Pagan (Washington, DC, USA)

12:00pm-1:30pm

Novel small molecules targeting alpha-synuclein aggregation for the treatment of Parkinson’s disease

E. Tsika, A. Davranche, E. Gabellieri, S. Nampally, J. Molette, S. Papin, H. Kroth, A. Pfeifer, D. Lowe, A. Muhs (Lausanne, Switzerland)

12:00pm-1:30pm

Novel training based on declarative memory cues improves gait perfromance in patients with Parkinson’s disease: A randomized clinical trial

M.E.P. Piemonte, E. Okamoto, K.R. Cardoso, T.P. Oliveira, C.S. Miranda, M. Pikel, F. Mendes, G.F. Xavier (Sao Paulo, Brazil)

12:00pm-1:30pm

Objective measurement in clinical care of patients with Parkinson’s disease

M. Horne, K. Kotschet, M. Braybrook (Parkville, Australia)

12:00pm-1:30pm

Objective measures of Parkinsonian motor symptoms using a continuously worn smartwatch

N. Fixler, L. Reitblat, A. Wagner, S. Cohen, M. Afek, P. Bonato, J.F. Daneault, N. Golabchi, S. Moore, A. Patel, C. Cho, L. Bataille (Petach Tikva, Israel)

12:00pm-1:30pm

Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease

N.K. Majbour, N.N. Vaikath, K.D. Dijk, M. Ardah, C.E. Teunissen, H.W. Berendse, W.D.J. Berg, O.M.A. El-Agnaf (Amsterdam, Netherlands)

12:00pm-1:30pm

Onset and stabilization of opicapone treatment effects in fluctuating Parkinson’s disease patients: Exploratory by-week efficacy analysis of pooled phase III studies

A. Lees, J. Ferreira, H. Reichmann, E. Tolosa, A. Santos, C. Oliveira, I. Oliveira, N. Lopes, J.F. Rocha, P. Soares-da-Silva (London, United Kingdom)

12:00pm-1:30pm

Opicapone in fluctuating Parkinson’s disease patients: OFF- and ON-time responder post-hoc analyses of pooled phase III studies

A. Lees, J. Ferreira, T. Müller, F. Stocchi, C. Oliveira, A. Santos, N. Lopes, J.F. Rocha, P. Soares-da-Silva (London, United Kingdom)

12:00pm-1:30pm

Osteopathic manipulative treatment in Parkinson’s disease: Preliminary results of a double blind sham-controlled cross-over study

S. Varanese, L. Cicchitti, G. Travaglini, V. Carafa, N. Modugno, S. Spinelli, F. Marsicano, M. Mistichelli, F. Marsicano, F. Giorgini, M. Verzella (Pozzilli, Italy)

12:00pm-1:30pm

Outpatient management of Parkinson’s disease: A review of medication changes made to address both motor and non-motor symptoms

B. Magennis, E.A. Donlon, E.M. Fallon, T. Lynch (Dublin, Ireland)

12:00pm-1:30pm

Pallidal versus subthalamic stimulation for PD: Beyond the motor effects

M.G. dos Santos Ghilardi, R.G. Cury, R.C.R. Martinez, M.J. Teixeira, E.R. Barbosa, E.T. Fonoff (Sao Paulo, Brazil)

12:00pm-1:30pm

PARK-OMM – An osteopathic manipulative medicine protocol to improve motor function and balance in Parkinson’s disease

S. Yao, K. de Vries, J. DiFrancisco-Donoghue, J. Mancini, M.K. Jung, G. Cheriyan, S. Curtis, A. Leder (Old Westbury, NY, USA)

12:00pm-1:30pm

Parkinson patient reported outcomes of voice and communication pre, post and 6 months following LSVT LOUD® and LSVT ARTIC

A.E. Halpern, L.O. Ramig, K. Freeman, J.L. Spielman (Denver, CO, USA)

12:00pm-1:30pm

Pathological findings from two Parkinson’s disease patients after intraputaminal GDNF infusion

T.R. Yamasaki, V.D. Smith, Y. Ai, D.M. Gash, P.T. Nelson, G.A. Gerhardt, J.T. Slevin (Lexington, KY, USA)

12:00pm-1:30pm

Patient case reports supporting a long-term effect of sub-anesthetic ketamine infusion in reducing L-DOPA-induced dyskinesias

S.J. Sherman, T. Falk (Tucson, AZ, USA)

12:00pm-1:30pm

PD COMM Pilot: A pilot randomised controlled trial of Lee Silverman voice treatment (LSVT) versus NHS speech and language therapy versus no intervention in Parkinson’s

C.M. Sackley, S. Patel, R. Woolley, N.J. Ives, C.E. Rick, F. Dowling, K. Wheatley, C. Smith, M. Brady, C.E. Clarke (London, United Kingdom)

12:00pm-1:30pm

PERFORM: Controlled study in fluctuating PD patients examining the effects of motor state on the outcomes resulting from a structured physical therapy (PT) program

J.P. Hubble, B. Fisher, K. Lyons, C. McLean, G. Petzinger, R. Pahwa (Louisville, KY, USA)

12:00pm-1:30pm

Peri-operative dopaminergic replacement protocol with rotigotine in Parkinson’s disease patients

L. Abraira del Fresno, L. Ispierto, A.M. Crespo, T. Canento, D. Vilas, M. Gonzalez, F. Sala, L. Morató, J. Sánchez-Ojanguren, R. Álvarez (Barcelona, Spain)

12:00pm-1:30pm

Peripheral neuropathies in Parkinson’s disease during levodopa-carbidopa intestinal gel treatment: Results from a long-term prospective follow-up study

A. Romagnolo, A. Merola, M. Zibetti, A. Bernardini, D. Cocito, C.A. Artusi, F. Dematteis, S. Angrisano, M.G. Rizzone, L. Lopiano (Turin, Italy)

12:00pm-1:30pm

Pharmacokinetic profile of ONO-2160/CD (levodopa prodrug/carbidopa) in animal and human

M. Nomoto, M. Nagai, N. Nishikawa, K. Yano, Y. Kagamiishi, M. Akisada, S. Saito, M. Yuba, T. Koyanagi, A. Takeda (Tohon Ehime, Japan)

12:00pm-1:30pm

Pisa syndrome in Parkinson’s disease: A mobile orfixed deformity?

E.I. Giyazitdinova, B.T. Muinjonov, G.S. Rakhimbaeva, Y.A. Musaeva, F.K. Shermukhamedova (Taskent, Uzbekistan)

12:00pm-1:30pm

Preclinical evaluation of sub-anesthetic ketamine infusion to reduce L-DOPA-induced dyskinesias: Is it a ‘chemical’ DBS?

T. Falk, M.J. Bartlett, T. Ye, L.B. Lazarus, M.L. Heien, S.L. Cowen, S.J. Sherman (Tucson, AZ, USA)

12:00pm-1:30pm

Predicting medication reduction in Parkinson’s disease patients after deep brain stimulation

S.A. Dodwell, C.E. Ashton, D.K. Simon, D. Tarsy, E. Papavassiliou, R. Alterman, L. Shih (Boston, MA, USA)

12:00pm-1:30pm

Predicting therapeutic effects of atomoxetine and citalopram on response inhibition in Parkinson’s disease

J.B. Rowe, C. Rae, C. Nombela, T. Ham, P. Vazquez, I. Coyle-Gilchrist, C.R. Housden, B.J. Sahakian, T.W. Robbins, Z. Yes (Cambridge, United Kingdom)

12:00pm-1:30pm

Progress in the development of small molecules based on the coumarin core as multifunctional neuroprotective agents

M.J. Matos, D. Viña, F. Rodríguez-Enríquez, S. Vilar, L. Santana, E. Uriarte (Santiago de Compostela, Spain)

12:00pm-1:30pm

Proprioceptive training as a means to enhance sensorimotor function in Parkinson’s disease

N. Elangovan, P. Tuite, J. Konczak (Minneapolis, MN, USA)

12:00pm-1:30pm

Rasagiline treatment for sleep disorders in Parkinson’s disease (RaSPar) – Double-blinded, randomized, placebo-controlled, placebo run-in-phase, polysomnography clinical trial

W. Schrempf, M. Fauser, K. Otto, M. Wienecke, C. Ossig, S. Brown, A. Maass, M.D. Brandt, U. Schwanebeck, X. Graehlert, H. Reichmann, A. Storch (Dresden, Germany)

12:00pm-1:30pm

Real world conversion of levodopa to a novel extended release levodopa preparation: Determining predictors and dose ratios

W. Ondo, P. Coss, M. Christie (Houston, TX, USA)

12:00pm-1:30pm

Real-life data on the use of levodopa carbidopa intestinal gel in Parkinson’s disease

J.T. Butler, D. Isaacs, C. Tolleson, R. Pierce, T. Davis (Nashville, TN, USA)

12:00pm-1:30pm

Recent result of indicative evaluation for deep brain stimulation of Parkinson’s disease patients

H. Saiki, S. Matsumoto (Osaka, Japan)

12:00pm-1:30pm

Reflex saccades changes can estimate long-term symptom progression in DBS STN and MED Parkinson’s disease patients (PD)

S. Szlufik, A. Przybyszewski, J. Dutkiewicz, P. Habela, T. Mandat, D. Koziorowski (Warsaw, Poland)

12:00pm-1:30pm

Rotigotine transdermal patch in Chinese patients with advanced Parkinson’s disease: A randomized, double-blind study

Z. Zhang, M. Asgharnejad, H. Xue, E. Surmann, L. Bauer (Beijing, People's Republic of China)

12:00pm-1:30pm

Safety and clinical effects of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson’s disease (PD): 81 to 130 weeks follow-up

B.J. Snow, E. Mulroy, M. Simpson, L. Macdonald, A. Bok, K. Taylor, J. Han, K. Durbin (Auckland, New Zealand)

12:00pm-1:30pm

Safety and efficacy of pardoprunox for patients with Parkinson’s disease: A meta-analysis

N. Elsagheer, H. Ahmed, A. Attia, K. Awad, E. Ezzat, M. Abd Elaleem Aziz, A. Negida (Beni Suef, Egypt)

12:00pm-1:30pm

Safety and tolerability of inhaled levodopa (CVT-301) administered to Parkinson’s disease patients with motor fluctuations

R. Pahwa, P. LeWitt, A. Corbin, R. Batycky, H. Murck (Kansas City, KS, USA)

12:00pm-1:30pm

Safety of opicapone in fluctuating Parkinson’s disease patients: Results of the 1-year extension of study BIPARK I

A. Santos, J. Ferreira, A. Lees, F. Stocchi, O. Rascol, N. Lopes, H. Gama, J.F. Rocha, P. Soares-da-Silva (Porto, Portugal)

12:00pm-1:30pm

Serum level of vitamin D3 in patients with neurodegenerative diseases compared to healthy adults and its correlation with the years spent from the initial diagnosis

A.N. Taravari (Skopje, Macedonia)

12:00pm-1:30pm

Smell perception and judgement in PD patients: Results of a study designed, conducted, analysed and reported by PD patients

J. Stamford (London, United Kingdom)

12:00pm-1:30pm

Speech and voice range profile in patients with Parkinson’s disease with deep brain stimulation: Preliminary data

G.L.A. Diaféria, A.E. Dias, M.J. Carvalho, R. Cury, E.R. Barbosa, E.T. Fonoff (São Paulo, Brazil)

12:00pm-1:30pm

STN-DBS in Parkinson’s disease with early motor complications – A 10 year follow-up

J. Muellner, F. Pineau, D. Maltête, J.L. Houeto, M.L. Welter, S. Navarro, P. Cornu, C. Bernasconi, Y. Agid, M. Schuepbach (Bern, Switzerland)

12:00pm-1:30pm

Subcutaneous apomorphine reduces OFF time and dyskinesias and improves quality of life in Parkinson’s disease (PD) – 5-year follow-up of patients in Greece

G.A. Tagaris, A. Skafida, D. Athanasopoulos, E. Trachani, S. Tsiara (Athens, Greece)

12:00pm-1:30pm

Subthalamic deep brain stimulation vs. intraduodenal levodopa infusion: A long-term retrospective comparative study

A. Merola, A.J. Espay, A. Romagnolo, A. Bernardini, M. Rosso, K.J. Espay, L. Rizzi, M. Zibetti, M. Lanotte, L. Lopiano (Torino, Italy)

12:00pm-1:30pm

Suggested criteria for patient selection for therapy with carbidopa/levodopa enteral suspension (CLES)

R.L. Rodriguez, T. Green, F. Rossi, A. Khaku, J. Slevin (Orlando, FL, USA)

12:00pm-1:30pm

Supplement use in PD is associated with delayed initiation of dopaminergic therapy

L. Chahine, S. Xie, K. Smith, C. Scordia, R. Purri, C. Linder, J. Duda, N. Dahodwala (Philadelphia, PA, USA)

12:00pm-1:30pm

Swallowing difficulties in patients with Parkinson’s disease and Parkinsonian syndromes

Y.O. Trufanov (Kyiv, Ukraine)

12:00pm-1:30pm

Taking specialist clinics into community nursing homes

T. Williams, S. Mahon, C. Thomas, B. Mohamed (Cardiff, United Kingdom)

12:00pm-1:30pm

Tear fluid as potential biomarker for the diagnosis of Parkinson’s disease

M. Börger, S. Funke, F. Maaß, A. Fischbach, M. Bähr, F. Grus, P. Lingor (Göttingen, Germany)

12:00pm-1:30pm

Telemedicine facilitates efficient and safe home titration of levodopa/carbidopa intestinal gel (LCIG) in patients with advanced Parkinson’s disease

T. Willows, N. Dizdar, D. Nyholm, H. Widner, P. Grenholm, U. Schmiauke, A. Urbom, K. Groth, J. Larsson, J. Permert, S. Kjellander (Huddinge, Sweden)

12:00pm-1:30pm

The application of mobile health technology to increase physical activity in persons with Parkinson’s disease

T.D. Ellis, T.R. DeAngelis, K. Hendron, J.T. Cavanaugh, N. Sullivan, L. Goehring, C.A. Thomas, M. Saint-Hilaire, N.K. Latham (Boston, MA, USA)

12:00pm-1:30pm

The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson’s disease: Experience from a case report

R. González-Maldonado, R. González-Redondo, C.G. DiCaudo (Granada, Spain)

12:00pm-1:30pm

The CNS moving voice program: Implementation of a dual voice and physical exercise program for Parkinson’s disease: An applicability study

R. Loureiro, J. Domingos, D. Peralta, J. Dean, J. Ferreira (Lisbon, Portugal)

12:00pm-1:30pm

The correlation between dietary fiber, fluid intake and constipation in patients with Parkinson’s disease

N. Kawashima, A. Tabata, A. Kumon, K. Miyashita, A. Sato, H. Onuma, S. Nakamura, E. Horiuchi, K. Hasegawa (Fujisawa, Japan)

12:00pm-1:30pm

The effect of levodopa-carbidopa intestinal gel on activities of daily living: Results from the observational MONOTREAT study in advanced Parkinson’s disease patients

R. Krüger, P. Lingor, T. Doskas, J. Henselmans, E.H. Danielsen, O. de Fabregues, A. Stefani, S.C. Sensken, J.C. Parra Riaza, K. Onuk, A. Yegin (Tübingen, Germany)

12:00pm-1:30pm

The effect of Mozart piano sonata on Parkinsonian tremor, rigidity and bradykinesia

A. Shoeybi, N. Olfati (Mashhad, Islamic Republic of Iran)

12:00pm-1:30pm

The effect of walking speed on postural stability in Parkinson’s disease fallers

M.H. Cole, M. Sweeney, Z.J. Conway, T.D. Blackmore, P.A. Silburn (Virginia, Australia)

12:00pm-1:30pm

The efficacy of tremor detection and suppression device in intractable rest tremor in patients with Parkinson’s disease

O. Jitkritsadakul, C. Thanawattano, C. Anan, R. Bhidayasiri (Bangkok, Thailand)

12:00pm-1:30pm

The impact of STN DBS on kinetic tremor in Parkinson’s disease patients

S. Szlufik, M. Szumilas, J. Dutkiewicz, D. Koziorowski, T. Mandat, E. Slubowska (Warsaw, Poland)

12:00pm-1:30pm

The influence of cerebellar transcranial direct current stimulation on skill acquisition in Parkinson’s disease

L. Lima de Albuquerque, K. Fischer, S. Jalene, M.R. Landers, B. Poston (Las Vegas, NV, USA)

12:00pm-1:30pm

The Luxembourg Parkinson’s study: Integrating the Lewy body composite risk score into a longitudinal study

M. Kerschenmeyer, P. Kolber, G. Hipp, K. Roomp, S.K. Mosch, A. Schweicher, L. Longhino, M. Falz, V.P. Satagopam, M. Gantenbein, M. Vaillant, F. Betsou, A. Chioti, R. Schreiner, R. Krüger (Belval, Luxembourg)

12:00pm-1:30pm

The NIC-PD-study –Baseline data of a randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson’s disease in Germany and the USA

W.H. Oertel, C. Brittinger, C. Kamp, K. Balthasar, K. Articus, M. Brinkman, C. Venuto, H. Mueller, M.M. Unger, K.M. Eggert, D. Vadasz, K. Kieburtz, J. Boyd (Marburg, Germany)

12:00pm-1:30pm

The novel COMT-inhibitor ODM-104 and optimized carbidopa in combination with modified release levodopa reduce levodopa fluctuation and increase minimum concentrations in healthy subjects, when compared to the standard carbidopa/levodopa/entacapone combination

J. Ellmen, J. Tuunainen, A. Holopainen, T. Sarapohja, M. Scheinin (Turku, Finland)

12:00pm-1:30pm

The potential therapeutic effect of intranasal administration of stem cells in rotenone model of Parkinson’s disease in mice

M. El-Gamal, M. Salama, M. Sobh, M. Emam, A. Abdalla, A. Lotfy, D. Sabry, M. El-Qotb, M. Sobh (Mansoura, Egypt)

12:00pm-1:30pm

Therapeutic yoga improves balance and balance confidence in Parkinson’s disease

F. Revilla, K. Woschkolup, A.A. Walter, B.L. Hawkins, E. Urrea-Mendoza, A.A. Schmid, J. Park, J. Sharp, M. VanPuymbroeck (Greenville, SC, USA)

12:00pm-1:30pm

Therapy escalation in Parkinson’s disease – The TEMP trial, a regional survey

F. Gandor, A. Kühn, J. Müller, F. Klostermann, T. Müller, D. Gruber, A. Lipp, A. Kivi, D. Kübler, F. Ehlen, G. Ebersbach (Beelitz-Heilstätten, Germany)

12:00pm-1:30pm

Upper limb motor tests are related to clinical ratings of motor function in advanced Parkinson’s disease

M. Memedi, S. Aghanavesi, D. Nyholm, H. Askmark, S.M. Aquilonius, R. Constantinescu, F. Bergquist, A. Medvedev, A. Ericsson, F. Ohlsson, S. Lycke, J. Spira, M. Senek, J. Westin (Falun, Sweden)

12:00pm-1:30pm

Use of nicotine gum to treat acute low blood pressure in Parkinson’s disease

J. DiFrancisco-Donoghue, A. Leder, M.K. Jung, W.G. Werner (Old Westbury, NY, USA)

12:00pm-1:30pm

Utility of IgGs subtypes in hemolytic anemia prevention and treatment maintenance in patients treated with continous infusion of apomorphine

P. Sanchez-Lozano, E. Suarez, R. Ribacoba (Gijon, Spain)

12:00pm-1:30pm

Utilization and longitudinal impact of amantadine use in Parkinson’s disease. National Parkinson Foundation (NPF) QII registry

V. Felix Saunders, T. Simuni, K. Li, S. Luo (Chicago, IL, USA)

12:00pm-1:30pm

Utilization and longitudinal impact of anticholinergic use in Parkinson’s disease. National Parkinson Foundation (NPF) QII registry

V. Felix Saunders, K. Li, S. Luo, T. Simuni (Chicago, IL, USA)

12:00pm-1:30pm

Validity and reliability of the test d evaluation des membres superieurs de personnes agees (TEMPA) to assess upper limb in Parkinson’s disease

C.L. Correa, P.R. de-Freitas, A.E. Lemos, S.M. Michaelsen, A. Swarowsky (Rio de Janeiro, Brazil)

12:00pm-1:30pm

VANTAGE trial: Three year outcomes of a prospective, multi-center trial evaluating deep brain stimulation with a new multiple-source, constant-current rechargeable system in Parkinson’s disease

L. Timmerman, R. Jain, L. Chen, T. Brucke, F. Seijo, E. Suarez San Martin, C. Haegelen, M. Verin, V. Visser-Vandewalle, M.T. Barbe, S. Gill, A. Whone, M. Porta, D. Servello, F. Alesch (Cologne, Germany)

12:00pm-1:30pm

Virtual rehabilitation: A therapy for parkinsonism?

B.S. Zeigelboim, G.J.B. Santos, M.I.R. Severiano, H.A.G. Teive, A.B.M. Lacerda, C.M. Porto (Curitiba, Brazil)

12:00pm-1:30pm

Virtual-reality balance training with Nintendo-Wii games improves dynamic balance in Parkinson’s disease patients

G.H. Lee (Cheon-An, Korea)

12:00pm-1:30pm

Voice harmonic amplitude differences before and after LSVT LOUD^TM in Parkinson’s disease

M.P. Cannito, L.O. Ramig, A.E. Halpern, J.L. Spielman (Lafayette, LA, USA)

12:00pm-1:30pm

When is the worst period of nocturnal hypokinesia in Parkinson’s disease? A sensor-based analysis

J. Sringean, P. Taechalertpaisarn, C. Thanawattano, R. Bhidayasiri (Nonthaburi, Thailand)

12:00pm-1:30pm

Whole body vibration therapy with exercise enhances motor function and improves quality of life in Parkinson’s disease

O.K. Gruder, D.Y. Edmonston, G.Q. Barr, C.G. Maitland (Tallahassee, FL, USA)